CD274 and neoplasm: BACKGROUND: Checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer immunotherapy; however, their efficacy remains limited in immune-excluded tumors characterized by scarce T-cell infiltration and a profoundly immunosuppressive tumor microenvironment (TME).